-$0.17 Earnings Per Share Expected for Aurinia Pharmaceuticals Inc (AUPH) This Quarter

Equities research analysts forecast that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will post earnings per share (EPS) of ($0.17) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Aurinia Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.14). Aurinia Pharmaceuticals posted earnings per share of ($0.16) in the same quarter last year, which indicates a negative year-over-year growth rate of 6.3%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 13th.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year earnings of ($0.71) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.62). For the next financial year, analysts forecast that the business will post earnings of ($0.73) per share, with EPS estimates ranging from ($0.95) to ($0.45). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.03). The firm had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 12,536.05% and a negative return on equity of 30.34%.

A number of brokerages have recently weighed in on AUPH. ValuEngine raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. HC Wainwright raised their target price on Aurinia Pharmaceuticals to $15.00 and gave the stock a “buy” rating in a research note on Monday, August 13th. BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $18.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, August 11th. Finally, Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average price target of $12.11.

Several institutional investors and hedge funds have recently modified their holdings of the company. Ironwood Investment Management LLC lifted its holdings in Aurinia Pharmaceuticals by 18.0% in the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after acquiring an additional 33,279 shares during the last quarter. Cornerstone Wealth Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $2,000,000. Creative Planning increased its holdings in shares of Aurinia Pharmaceuticals by 8.2% in the 2nd quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock valued at $964,000 after acquiring an additional 13,000 shares during the period. Stanley Laman Group Ltd. purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $276,000. Finally, Stifel Financial Corp increased its holdings in shares of Aurinia Pharmaceuticals by 98.4% in the 1st quarter. Stifel Financial Corp now owns 21,718 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 10,772 shares during the period. Hedge funds and other institutional investors own 24.92% of the company’s stock.

Shares of NASDAQ:AUPH traded down $0.13 during trading on Wednesday, reaching $5.82. The company had a trading volume of 2,607 shares, compared to its average volume of 607,066. The firm has a market cap of $566.53 million, a P/E ratio of -6.30 and a beta of 2.12. Aurinia Pharmaceuticals has a twelve month low of $4.41 and a twelve month high of $6.92.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Further Reading: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply